NovaBridge Advances Clinical Pipeline with Key Milestones and Leadership Shifts
Event summary
- NovaBridge reported $215.9 million in cash reserves as of June 30, 2026, sufficient to fund operations through 2028.
- Givastomig, a potential first-in-class Claudin 18.2-targeted immuno amplifier, is set to initiate a Phase 3 study by year-end 2026.
- VIS-101, a tetravalent VEGF-A × ANG-2 peptibody for retinal diseases, is progressing toward a Phase 2b study in the second half of 2026.
- Srishti Gupta, MD, MPP, was appointed CEO to strengthen strategic oversight and governance.
The big picture
NovaBridge is positioning itself as a biotechnology company that identifies and develops differentiated therapeutic assets efficiently. The strategic appointments and clinical milestones reflect its focus on long-term value creation for patients and shareholders. The company's ability to execute on its pipeline and maintain financial stability will be critical in a competitive biotech landscape.
What we're watching
- Clinical Execution
- Whether NovaBridge can successfully initiate and complete the Phase 3 study for givastomig by year-end 2026, given the potential Accelerated Approval Pathway.
- Pipeline Momentum
- The pace at which VIS-101 advances through Phase 2b and into a global Phase 3 program in 2027, and its potential to become a best-in-class treatment for retinal diseases.
- Financial Sustainability
- How NovaBridge manages its cash runway and R&D expenses to support multiple clinical and strategic milestones through 2028.
Related topics